Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3SBio And AMAG Ink Deal To Develop Ferumoxytol In China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's 3SBio Pharmaceutical and U.S.-based AMAG Pharmaceuticals have entered into a strategic partnership to develop and commercialize AMAG's nanoparticle agent Ferumoxytol in China, the two companies announced May 27

You may also be interested in...



Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?

SHANGHAI - While reporting strong growth in the third quarter, New York-listed Chinese pharma Simcere focused attention on its recent deal with Bristol-Myers Squibb to co-develop BMS-817378, a small molecule MET/VEGFR-2 inhibitor now in preclinical development

Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?

SHANGHAI - While reporting strong growth in the third quarter, New York-listed Chinese pharma Simcere focused attention on its recent deal with Bristol-Myers Squibb to co-develop BMS-817378, a small molecule MET/VEGFR-2 inhibitor now in preclinical development

China's 3SBio Signs Deal For Isotechnika's Transplant/Immune System Drug Voclosporin After U.S. Delays

HONG KONG - Canada's Isotechnika Pharma has signed a new deal with Chinese drug maker 3SBio on the development and commercialization of Isotechnika's voclosporin, which helps suppress the immune system's rejection of transplanted organs

Related Content

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel